Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

BACKGROUND Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse. Recent genomewide analyses have identified a high frequency of DNA copy-number abnormalities in ALL, but the prognostic implications of these abnormalities have not been defined. METHODS We studied a cohort of 221 children with high-risk B-cell-progenitor ALL with the use of single-nucleotide-polymorphism microarrays, transcriptional profiling, and resequencing of samples obtained at diagnosis. Children with known very-high-risk ALL subtypes (i.e., BCR-ABL1-positive ALL, hypodiploid ALL, and ALL in infants) were excluded from this cohort. A copy-number abnormality was identified as a predictor of poor outcome, and it was then tested in an independent validation cohort of 258 patients with B-cell-progenitor ALL. RESULTS More than 50 recurring copy-number abnormalities were identified, most commonly involving genes that encode regulators of B-cell development (in 66.8% of patients in the original cohort); PAX5 was involved in 31.7% and IKZF1 in 28.6% of patients. Using copy-number abnormalities, we identified a predictor of poor outcome that was validated in the independent validation cohort. This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS. The gene-expression signature of the group of patients with a poor outcome revealed increased expression of hematopoietic stem-cell genes and reduced expression of B-cell-lineage genes, and it was similar to the signature of BCR-ABL1-positive ALL, another high-risk subtype of ALL with a high frequency of IKZF1 deletion. CONCLUSIONS Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.

[1]  R. Arceci,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .

[2]  W. Westerhof,et al.  Effect of one session of ER:YAG laser ablation plus topical 5Fluorouracil on the outcome of short‐term NB‐UVB phototherapy in the treatment of non‐segmental vitiligo: a left–right comparative study , 2008, Photodermatology, photoimmunology & photomedicine.

[3]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[4]  L. Naldi,et al.  Randomized controlled trial comparing the effectiveness of 308‐nm excimer laser alone or in combination with topical hydrocortisone 17‐butyrate cream in the treatment of vitiligo of the face and neck , 2008, The British journal of dermatology.

[5]  Rob Pieters,et al.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. , 2008, Cancer cell.

[6]  S. Hunger,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.

[7]  T. Hubbard,et al.  Large-Scale Mutagenesis in p19ARF- and p53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks , 2008, Cell.

[8]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[9]  Leslie L Robison,et al.  Acute lymphoblastic leukaemia , 2018, Radiopaedia.org.

[10]  Carl W. Miller,et al.  Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. , 2007, Blood.

[11]  R. Pieters,et al.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.

[12]  J. Hehir-Kwa,et al.  High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression , 2007, Leukemia.

[13]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[14]  R. Tibshirani,et al.  On testing the significance of sets of genes , 2006, math/0610667.

[15]  R. Tibshirani,et al.  Prediction by Supervised Principal Components , 2006 .

[16]  H. Cavé,et al.  The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. , 2006, Haematologica.

[17]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Relling,et al.  Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia , 2005, Cancer.

[19]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[20]  Jeanne Kowalski,et al.  Microarray and Serial Analysis of Gene Expression Analyses Identify Known and Novel Transcripts Overexpressed in Hematopoietic Stem Cells , 2004, Cancer Research.

[21]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[22]  J. Downing,et al.  Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.

[23]  C. Garvie,et al.  Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-alpha gene transcription by Pax-5 (BSAP). , 2003, Nucleic acids research.

[24]  E. Cook,et al.  Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Rebollo,et al.  Ikaros, Aiolos and Helios: Transcription regulators and lymphoid malignancies , 2003, Immunology and cell biology.

[26]  G. Gustafsson,et al.  Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92 , 2002, Leukemia.

[27]  C. Chabannon,et al.  Forced expression of the Ikaros 6 isoform in human placental blood CD34(+) cells impairs their ability to differentiate toward the B-lymphoid lineage. , 2001, Blood.

[28]  F. Behm,et al.  Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital , 2000, Leukemia.

[29]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[30]  A. Fisher,et al.  Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. , 2000, Genes & development.

[31]  D. Nemazee,et al.  B‐cell antigen receptor competence regulates B‐lymphocyte selection and survival , 2000, Immunological reviews.

[32]  A. Look,et al.  Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse , 1999 .

[33]  H. Sather,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.

[34]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[35]  C. Pratt,et al.  St. Jude Children's Research Hospital. , 1997, Pediatric hematology and oncology.

[36]  K. Georgopoulos,et al.  Zinc finger‐mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. , 1996, The EMBO journal.

[37]  K. Georgopoulos,et al.  A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma , 1995, Cell.

[38]  A. Sharpe,et al.  The ikaros gene is required for the development of all lymphoid lineages , 1994, Cell.